Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Remedy, in Mixture with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Sufferers with Excessive-Threat Stage III/IV Melanoma Following Full Resection versus KEYTRUDA Articles